IL17A and autoimmune disease: Given the ability of IL-17 to promote RA pathology, it is plausible to suggest that pharmacologic strategies aimed at blocking or suppressing IL-17, particularly cellular Th17 function, may deserve attention as a potential therapeutic strategy for autoimmune diseases.